Pfizer cuts 2026 revenue outlook amid COVID-19 & patent losses

The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion

Accenture invests in Ryght AI to revolutionize clinical trials

Ryght AI tackles these hurdles with its AI Site Twin platform

FDA accepts Sentynl Therapeutics CUTX-101 NDA resubmission

If approved, CUTX-101 will be the first and only FDA approved treatment available for Menkes disease

Neuren partner Acadia bags FDA go-ahead for new DAYBUE STIX powder for Rett Syndrome

The new powder formulation gives children and adults living with Rett syndrome greater flexibility and choice in dose volume and taste

Emcure Pharmaceuticals appoints Barnona Basu as Director – Marketing (India)

Merck wins key EU backing to expand use of PAH Drug WINREVAIR

WINREVAIR is currently the first and only activin signalling inhibitor approved for PAH across all 27 EU member states

OTR Therapeutics and Zealand Pharma join forces to target metabolic diseases

The companies aim to expand treatment options for millions living with metabolic disorders

Formation Bio snaps up global rights to next-gen CNS TYK2 inhibitor from Lynk Pharma

LNK01006 is designed to deliver potent, selective inhibition of TYK2-mediated cytokine signaling with central nervous system exposure

Granules India receives official 2025 CDP rating

The company had achieved the highest "A" rating in Climate Change

Dr. Reddy's Laboratories announces SBTi targets

Dr. Reddy's commits to achieving Net Zero greenhouse gas emissions across its value chain by FY 2045